Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19421658 | 0.91 | AOC3 (0.43) | PRMT6RAB9APDE1APDE1BNTRK1 | |
| SCHEMBL19430410 | 0.91 | PRMT6 (0.41) | PRMT6RAB9APDE1APDE1BNTRK1 | |
| SCHEMBL17606388 | 0.90 | NTRK1 (0.46) | PRMT6RAB9APDE1APDE1BNTRK1 | |
| SCHEMBL19430127 | 0.87 | RAB9A (0.44) | PRMT6RAB9AEZH2KDM5BL3MBTL1 | |
| SCHEMBL19429947 | 0.87 | PDE1B (0.44) | PRMT6RAB9APDE1APDE1BNTRK1 | |
| SCHEMBL19429798 | 0.85 | RAB9A (0.42) | PRMT6RAB9APDE1APDE1BEZH2 | |
| SCHEMBL19430008 | 0.84 | KDM5B (0.44) | PRMT6RAB9AEZH2KDM5BGBA1 | |
| SCHEMBL19429795 | 0.84 | RAB9A (0.41) | PRMT6RAB9APDE1APDE1BEZH2 | |
| SCHEMBL19430383 | 0.84 | PRMT6 (0.40) | PRMT6RAB9ANTRK1EZH2KDM5B | |
| SCHEMBL19430136 | 0.84 | RAB9A (0.40) | PRMT6RAB9APDE1APDE1BEZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT6 4/4885RAB9A 1186/4885PDE1A 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.